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Abstract
Background: Chlamydial infection is the most common notifiable disease in Australia, Europe and the US.
Australian notifications of chlamydia rose four-fold from 20,274 cases in 2002 to 80,846 cases in 2011; the majority
of cases were among young people aged less than 29 years. Along with test positivity rates, an understanding of
the number of tests performed and the demographics of individuals being tested are key epidemiological
indicators. The ACCESS Laboratory Network was established in 2008 to address this issue.
Methods: The ACCESS Laboratory Network collected chlamydia testing data from 15 laboratories around Australia
over a three-year period using data extraction software. All chlamydia testing data from participating laboratories
were extracted from the laboratory information system; patient identifiers converted to a unique, non-reversible
code and de-identified data sent to a single database. Analysis of data by anatomical site included all specimens,
but in age and sex specific analysis, only one testing episode was counted.
Results: From 2008 to 2010 a total of 628,295 chlamydia tests were referred to the 15 laboratories. Of the 592,626
individual episodes presenting for testing, 70% were from female and 30% from male patients. In female patients,
chlamydia positivity rate was 6.4% overall; the highest rate in 14 year olds (14.3%). In male patients, the chlamydia
positivity rate was 9.4% overall; the highest in 19 year olds (16.5%). The most common sample type was urine
(57%). In 3.2% of testing episodes, multiple anatomical sites were sampled. Urethral swabs gave the highest
positivity rate for all anatomical sites in both female (7.7%) and male patients (14%), followed by urine (7.6%
and 9.4%, respectively) and eye (6.3% and 7.9%, respectively).
Conclusions: The ACCESS Laboratory Network data are unique in both number and scope and are representative
of chlamydia testing in both general practice and high-risk clinics. The findings from these data highlight much
lower levels of testing in young people aged 20 years or less; in particular female patients aged less than 16 years,
despite being the group with the highest positivity rate. Strategies are needed to increase the uptake of testing in
this high-risk group.
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Background
Chlamydia trachomatis is the most commonly notified
infection in Australia [1] with notifications increasing
from 20,274 cases in 2002 to 80,846 cases in 2011 [1].
The World Health Organization estimates there are over
100 million new cases globally each year [2,3] resulting
in a substantial cost to health systems for management
of diseases including pelvic inflammatory disease, ectopic
pregnancy and infertility [2,4,5].
In Australia, routine chlamydia testing using culture or
direct immunofluorescence assays that detect elementary
bodies by fluorescent microscopy [6,7] started in the 1980s.
These tests were superseded by antigen detection using
enzyme immunoassay [6,8-12] and in the 1990’s nucleic
acid testing (NAT) [13-16] was introduced. Due to
the superior analytical sensitivity of NAT over other
technologies, it is considered the gold standard test for
C. trachomatis [8] and is used universally in Australia
for routine testing.
Pathology testing in Australia is covered by the national
universal health insurance “Medicare”. Only Australian
clinicians and some accredited healthcare professionals
may request pathology testing. Several recommendations
exist for opportunistic and routine chlamydia screening in
priority populations in various clinical settings; whilst
guidelines differ, the populations most commonly high-
lighted for routine and/or opportunistic screening include
sexually active young people, Indigenous people, recent
sexual contacts of infected men and women and gay,
bisexual and other men who have sex with men (MSM)
[1-4]. For chlamydia screening in men, a first-void urine,
taken more than one hour after previous void, or urethral
swab, but only when a discharge is present, are recom-
mended [17]. Endocervical or vaginal swabs or first-void
urine samples are recommended for women. Ano-rectal
swabs are recommended if clinically indicated, particular
with MSM. In addition, MSM are recommended to have
annual rectal swab irrespective of symptoms or more
frequently if engaging in unprotected anal sex or if more
than 10 partners in a year [17,18]. Pharyngeal swabs for
chlamydia are not generally indicated. Parental consent is
not required from young people aged <18 years when
assessed by a clinician to be competent to give consent [19].
Despite passive surveillance of positive cases in Australia,
until recently there was no nationally-coordinated system-
atic surveillance system to monitor the number of tests
conducted or enhanced surveillance data to elucidate who
was being tested. These are important epidemiological
indicators that are not commonly collected nor reported
but that are particularly useful for the interpretation of
positive chlamydia tests [20]. The availability of denomin-
ator data is particularly useful because it allows the number
of positive tests to be interpreted in the light of testing
patterns, providing a positivity rate that can be used as an
indicator of the long-term outcome of prevention pro-
grams. For example, without these denominator data, it is
not possible to ascertain if the increase in chlamydia notifi-
cations over time is due to greater transmission [21,22],
variation in bacterial strains [23,24] or laboratory technol-
ogy [25,26], an increase in testing, or a mixture of each of
these variables [20]. Prevalence studies could provide this
information, but they are extremely costly to run. Further-
more, they are not able to provide an accurate picture of
trends and practices of chlamydia testing in a population,
an important measure in itself.
Understanding the epidemiology of chlamydia and
identifying high-risk groups aids in the implementation
of prevention and intervention programs. Priority popu-
lations in Australia include young people aged 25 years
or less, men who have sex with men (MSM), Aboriginal
and Torres Strait Island people, and sex workers [27].
Various health departments have implemented health pro-
motion campaigns targeting priority populations [28-31]
and have encouraged general practitioners to increase
testing of young people [32-36]. Sentinel surveillance sys-
tems have generally found that the increase in chlamydia
notifications was due to increases in both the number of
tests and an increase in the proportion of positive test re-
sults [37-42]. However, these studies usually are confined
to clinics managing individuals at higher risk of infection
compare with the general population [37,43]. There is lim-
ited information on population-level changes in testing
behaviour.
In 2007, the Australian Collaboration for Chlamydia
Enhanced Sentinel Surveillance (ACCESS) program was
established [44]. Described in detail elsewhere [44],
ACCESS is referred to as being “enhanced” because it
consists of five clinical sentinel surveillance networks:
family planning clinics, Aboriginal community controlled
health services, sexual health clinics, antenatal clinics, and
general practice clinics; plus a laboratory network. The
aim of the ACCESS Laboratory Network was to describe
characteristics and trends in chlamydia testing and diag-
nosis in public and private laboratories nationally, provid-
ing stakeholders with a large quantity of population data
on testing frequency and outcomes, and demographics
of people who undergo chlamydia testing in most
states of Australia. This paper presents the findings of




Data were collected through the ACCESS Laboratory
Network, a national network of public and private
laboratories. Ethics approval was granted by the Alfred
Hospital Ethics Committee (Project 90/12). As the data
extracted contained no patient identifers, consent from
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each individual included in the study was not required. All
Australian laboratories testing for chlamydia at the time
of recruitment (approximately 40 laboratories) were in-
vited to participate at relevant workshops, newsletters,
and through email, telephone calls and on-site visits. Of
the laboratories approached, 15 laboratories participated
in the Laboratory Network, including five from Victoria,
four from Queensland, three from New South Wales, two
from South Australia and one from Tasmania. Four were
private and 11 were public laboratories.
Participating laboratories employ a range of commercial
and in-house NAT detecting both chlamydia and gonor-
rhoea, and usually both tests are performed irrespective of
the request. All laboratories have participated in one or
more external quality assessment scheme and a quality
control program provided by NRL. During the period of
time of the study, some laboratories used assays that were
unable to detect some known variants of chlamydia, how-
ever there were very few imported cases circulating in the
Australian population at that time [45].
Data collection, encryption and transfer
Data collected from the 15 participating laboratories
included all chlamydia test records conducted between 1
January 2008 and 31 December 2010. The laboratories
that declined the invitation to participate did so due to
lack of time or resources. Data were extracted in March
2011. Two laboratories did not provide data for 2010.
Data were collected directly from laboratory information
systems (LIS) using electronic data extraction software
(GRHANITE; University of Melbourne, Faculty of Medi-
cine, Australia) [46]. GRHANITE automatically accessed
the extracted data file that was stored within the security
of the LIS and encrypted the patient identifiers into a
non-reversible and de-identified statistical linkage keys
that are unique to each individual. Core variables ex-
tracted included the de-identified statistical linkage keys,
gender, date of birth, postcode of residence, sample type,
date of request, date of result, and test result. Tests
results were provided on all patients irrespective of age
by all participating laboratories except one Victorian
laboratory where the data in 2008 only pertained to
those individuals aged 16 to 29 years. The de-identified
data were then electronically transmitted to a secure ser-
ver located at the Burnet Institute, Melbourne, Australia,
decrypted and uploaded to an MS SQL database.
Data analysis
Data were excluded when patient’s age was greater than
90 years, 0 or left blank; if the result was equivocal or
missing or if there was a site/gender mismatch e.g. a
cervical swab from a male patient, although this may have
excluded some valid results from transgender individuals.
The anatomical sites were categorised into: cervical (swabs),
cervical (thin prep), eye, genital (including all non-
cervical, −urethral and -vaginal samples), rectal, throat, ur-
ethral, urine, vaginal, other (including skin, internal organ,
body fluids) and unknown.
All test results, including repeat tests, were used in the
analysis. The percentage positive for chlamydia was
calculated by dividing the total number of positive results
by the total number of tests performed, stratified by calen-
dar year, age, sex and anatomical site. Analysis by anatom-
ical site included all specimens, but in age and sex specific
analysis when an individual had multiple sites sampled on
the same day, only one test (episode) was counted. The
testing episode was considered chlamydia positive if any
of the specimens were positive.
Stata statistical analysis software (StataCorp, Tx., USA)
was used for all analyses. Trends over time were deter-
mined using a chi-squared (Chi2) test for trends. Binomial




A total of 628,295 chlamydia tests were collected, of which
11,575 (1.8%) tests were excluded due to: patient’s age
(>90 years or 0 years) or age was unavailable (n = 3,243),
unassigned gender (n = 2,030), equivocal or missing re-
sults (n = 5,035) and site/gender mismatch (n = 1,267).
Data from the remaining 616,720 tests were included in
the analysis of results by specimen site. Of the thirteen
laboratories that provided chlamydia test results for all
three years there were 167,453 tests in 2008, 228,202 in
2009 and 198,948 in 2010. A further 24,094 specimens,
which represented samples taken from multiple anatom-
ical sites during the same testing episode, were excluded
for analysis by age and sex, leaving a total of 592,626 tests.
Number and type of tests
Of the 592,626 testing episodes, 415,069 (70%) tests
were from female and 177,557 (30%) from male patients;
417,570 tests (70%) were from individuals aged 16–29
years (Table 1). The highest number of tests was among
men and women aged between 20 and 29 (Figure 1). In
female patients, 55.4% of samples were urine specimens
and 29.3% were cervical (swabs) (Figure 2). The majority
(79.6%) of samples collected from male patients were
urine specimens (Figure 3).
Chlamydia positivity by age and sex
There were 43,192 (7.3%, 95 CI: 7.2 - 7.4%) chlamydia
positive tests; 26,544 (6.4%, 95 CI: 6.3-6.5) in female and
16,648 (9.4% (95 CI: 9.2-9.5) in male patients. Between
2008 to 2010, the chlamydia positivity in female patients
aged 16–29 years was 7.7% (95 CI: 7.6-7.8). The highest
positivity rate among females was among 14 and 15 year
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olds (14.3% [95% CI 12.8-15.9] and 13.9% [95% CI 12.9-
15.0] respectively) and positivity rate declined as the age
of the patients increased (Figure 1). Chlamydia positivity
in male patients aged 16–29 years over the three year
period was 12.0% (95% CI: 11.8-12.2), peaking at 16.5%
(95% CI 15.6-17.3) positive at age 19 years (Figure 1).
From 2008 to 2010 there was a significant increase in
chlamydia positivity for 16 to 19 year old females
(11.9% to 12.7%, p < 0.01) and males (14.2% to 16.4%,
p < 0.01) and female patients aged 30–39 years (2.4%-
2.8%, p = 0.02).
Positivity by specimen type and anatomical site
Urethral swabs, which are recommended only when a
discharge is present, gave the highest positivity rate for
all anatomical sites in both female 7.7% (Figure 2) and
male patients 13.8% (Figure 3). The overall positivity rate
Table 1 Chlamydia test data collected from 15 Australian laboratories obtained over a three-year period displayed by year
Sex and age in years Chlamydia tests Positive tests Positivity rates
2008 2009 2010 2008 2009 2010 2008 2009 2010 P*
(n) (n) (n) (n) (n) (n) (%) (%) (%)
Female patients
<16 2,174 3,172 2,761 279 352 367 12.8 11.1 13.3 0.56
16-19 21,403 25,265 22,190 2,539 2,937 2,826 11.9 11.6 12.7 <0.01
20-24 40,124 48,076 42,943 3,237 3,780 3,562 8.1 7.9 8.3 0.2
25-29 32,570 38,999 34,178 1,468 1,723 1,457 4.5 4.4 4.3 0.14
30-39 16,161 27,834 20,009 382 643 554 2.4 2.3 2.8 0.02
40+ 8,711 16,734 11,765 93 218 127 1.1 1.3 1.1 0.98
all 121,143 160,080 133,846 7,998 9,653 8,893 6.6 6 6.6 0.50
Male patients
<16 895 1,145 1,242 77 82 111 8.6 7.2 9 0.64
16-19 6,019 7,307 6,710 856 1,072 1,102 14.2 14.7 16.4 <0.01
20-24 14,789 17,794 16,205 1,979 2,328 2,165 13.4 13.1 13.4 0.99
25-29 13,431 15,597 13,922 1,261 1,404 1,253 9.4 9 9 0.28
30-39 8,070 12,458 9,583 488 775 581 6.1 6.2 6.1 0.91
40+ 8,425 13,747 10,218 287 513 314 3.4 3.7 3.1 0.17
all 51,629 68,048 57,880 4,948 6,174 5,526 9.6 9.1 9.6 0.93
Total 172,772 228,128 191,726 12,946 15,827 14,419 7.5 6.9 7.5 0.56
*The number of tests per year and the percentage positivity by age group and gender are shown with the differences between the percentage positivity estimated








































Figure 1 Chlamydia testing numbers and positivity rates by age and sex, 2008–2010.
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for eye swabs was 6.3% (Figure 2) for female and 7.9%
(Figure 3) for male patients.
In 16–29 year old female patients, the chlamydia posi-
tivity was 10.0% in urethral swabs, 8.8% in urine speci-
mens, 7.8% in vaginal swabs, 6.7% in cervical swabs, 5.2%
in rectal swabs, 3.6% for cervical (thin prep) and 1.7% in
throat swabs over the three-year period. Male patients
aged between 16–29 years had chlamydia positivity of
17.4% in urethral swabs, 12.2% in urine specimens, 5.2%
in rectal swabs and 1.3% in throat swabs. The highest
chlamydia positivity in male rectal swabs was seen in
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Figure 3 Chlamydia test data on male patients by anatomical site and age.
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Discussion
To our knowledge, the ACCESS Laboratory Network is
the first national surveillance system designed to collect
and analyse chlamydia testing data that are representative
of a range of clinical sites, including general practice, ante-
natal clinics, sexual health clinics and family planning
clinics as well as hospital in- and out-patients clinics. Data
collected by the ACCESS Laboratory Network is unique
in size and scope, providing data on almost 630,000 tests
from 590,000 episodes from 15 Australian laboratories
over a three-year period. In 2009, 62,660 chlamydia infec-
tious were reported to state and territory health author-
ities under the provisions of the public health legislation
in their jurisdiction [47]. In the same year, the ACCESS
Laboratory Network collected 15,827 positive results,
representing just over 25% of all chlamydia notifications
nationally. The participating laboratories provided a good
representation of chlamydia testing across Australia as
the population serviced included high risk individuals,
general practice, and hospital in- and out-patients. Al-
though coverage was not complete, there is no other system
in Australia which can provide such a large, representative
overview of chlamydia testing and positivity.
Data presented here reveal higher and increasing chla-
mydia positivity rates among young people, particularly
those aged younger than 16 years, and highlights the
importance of ongoing population-level surveillance to
monitor trends in testing and positivity in a broader popu-
lation than traditionally captured in sentinel surveillance
systems.
Of particular note, the highest positivity rate was
found in female patients aged 14–15 years, although
relatively few tests were performed. It is quite possible
that only individuals in this demographic that have en-
gaged in high risk activities are seeking testing; therefore
increasing the positivity rate. However, there are limited
data on chlamydia testing, positivity, and risk behaviours
among 12–15 year olds as many studies are limited to
collecting data on individuals aged 16 years and older.
Evidence suggests that many young people aged younger
than 15 years are sexually active - 23% of young people
surveyed at a music festival reported their first sexual
intercourse at 15 years or less (unpublished data) – and
thus data on this age group collected in the ACCESS
Laboratory Network is both unique and paramount to
monitoring emerging trends in infection. The high
positivity rate found in this study highlights the need
for ongoing research with this vulnerable age group,
as well as potential modifications to the target ages
for chlamydia control programs. Even though these data
are anonymised, ethics committees would not allow the
collection of data on patients less than 16 years in
the ACCESS clinical networks: this policy should be
reconsidered.
Our findings reveal the majority of chlamydia tests
were performed on female patients, though positivity
was higher among male compared with female patients.
This finding is consistent with studies that show that
approximately 50% of men with chlamydia in clinical
settings will have symptoms of urethritis, while asymp-
tomatic men with chlamydia are more often tested after
being a contact of a woman with chlamydia [48,49].
An important finding presented here is the significant
increase in positivity rate from 2008 to 2010 in both
female and male patients aged 16–19 years. This may be
due to an increase in transmission in this age group
related to changes in sexual behaviour, increased targeting
of higher risk individuals within this population or a bias
in the collection of data [21,42]. An increase in positivity
was also observed among female patients aged 16–19
years in the ACCESS General Practice Network (8.7% in
2008 to 12.6% in 2010 among females) whilst positivity
among male patients aged 16–19 years remained stable
(19.6% in 2008 and 19.0% in 2010) [50]. The Victorian
Network for Sentinel Surveillance of STI also found an
increase in chlamydia positivity among women tested
(from 5.1% to 6.3%) [42]. Continued monitoring is needed
to ascertain if this increase in positivity rates continues
over time and if an increase is also observed among young
men in order to inform and evaluate national and state
chlamydia control programs.
Australian chlamydia prevalence estimates vary by age
group, population and setting where testing was con-
ducted. A recent systematic review estimated the pooled
prevalence for women <25 years in studies conducted
post-2005 in community or general practice settings,
was 5.0% [51]; our study suggests a higher positivity
among young women however is likely larger due to the
inclusion of tests conducted at sexual health clinics in
the data, and therefore representative of prevalence at a
range of clinical settings. Chlamydia positivity in women
aged 16–29 years was higher in urine (8.8%) and vaginal
swabs (7.8%) than cervical swabs (6.7%), despite chlamydia
infecting the columnar epithelial cells of the cervix. The
lower positivity rate in cervical swabs may be due to
sampling of the cervix being performed at the time of
cytological screening whereas urine and vaginal specimens
were collected when the patient is symptomatic or per-
ceived to be at high risk. This is supported by the low rates
of positivity in cervical (thin prep) specimens (3.6%) and
that the positivity rate of cervical swabs in women over
the age of 30 years is less than 2%.
Almost 80% of samples from male patients tested
for chlamydia were urine specimens. Over the three-year
period chlamydia positivity was highest in men aged
16–19 years (15.1%) although men aged 20–24 years
had more tests performed. Of concern, the positivity rate
in men aged 16–19 years increased significantly over the
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three year period. An increase in positivity among young
males was also observed in the ACCESS Family Planning
Clinic Network [48,52] but not in the ACCESS General
Practice Clinic Network [50]. The increased positivity
could potentially be a result of improved targeting of chla-
mydia testing or due to a real increase in the population
prevalence; targeted studies are required to investigate this
further. Fewer males were tested than females, which is
likely related to different health seeking behaviour, with
men testing more in response to symptoms or contacts,
and women presenting more routinely for opportunistic
asymptomatic screening during health service visits for
other reasons such as seeking contraceptive advice or
cervical screening. The high positivity found among young
men suggests that increased screening is warranted.
Rectal swabs from male patients (5.2% positivity) en-
abled the ACCESS Laboratory Network to assess a proxy
measure of chlamydia positivity in MSM. Estimates of
chlamydia positivity rates in MSM are limited in Australia,
with ongoing estimates with large sample sizes lacking
[53]. This finding was lower than estimates of positivity
(at any anatomical site) among MSM from the ACCESS
sexual health service network (7.2%) [44] and Victorian
Primary Care Network for Sentinel Surveillance (6.4%)
[54], both of which estimate prevalence for MSM that
seek sexual health care at either sexual health services or
gay men’s health clinics and are thus are not representa-
tive of the broader MSM population. The lower positivity
rate may be due to the inclusion of lower-risk MSM in the
study population compared with higher risk men that
present to sexual health services and gay men’s clinics.
Furthermore, including only rectal chlamydia is likely to
underestimate chlamydia positivity among MSM by ex-
cluding urethral, pharyngeal, and other sites. Nonetheless,
this finding highlights the potential for data collected
through a laboratory network to complement sentinel
surveillance data when interpreting trends in positivity in
priority populations.
The highest positivity rate of male rectal swabs was in
those aged 30–39 years and is consistent with Victorian
data on chlamydia positivity by age [54]. However, the
chlamydia positivity rates observed for rectal and throat
swabs should be interpreted with caution [55-57].
The commercial chlamydia NAT assays used in labora-
tories are only validated for samples that have a high likeli-
hood of containing infected epithelial cells e.g. cervical
swabs, vaginal swabs or first stream urine specimens.
However, the analysis showed that many other samples
types, such as throat swabs and rectal swabs, are com-
monly referred to pathology laboratories. These sample
types must be validated by the laboratory prior to being
tested but often the validation may not occur or not done
comprehensively due to the difficulties obtaining ap-
propriate samples in sufficient quantity. That being said, a
recent report indicates that rectal swabs are an effective
sample type for the diagnosis of chlamydia infection [57].
In Australia, the only current general population data
source for chlamydia testing is from Medicare Benefit
Schedule data, which reported only 850,779 tests con-
ducted in Australia between 2008 and 2010 (786,455 in
the states and territories with ACCESS Laboratory
Network sites); these data only include tests for which
a Medicare benefit was claimed and exclude testing
undertaken in state-funded public facilities as well as
many sexual health services. It also provides no data
on positivity rates [58]. Therefore, data collected in this
study is unique in that it collates data from a broader range
of sites and is more representative of overall population-
based chlamydia testing and positivity patterns.
The current study has some limitations. Despite the
ACCESS Laboratory Network providing a very large
sample size, the data reflect only a subset of the total
testing in Australia. The actual proportion is unable to
be discerned due to the lack of data on chlamydia testing
in Australia. One Victorian laboratory only reported
results in 2008 for individuals aged 16–29 years due to
installation issues and two laboratories were unable to
provide data for 2010 due to changes in their LIS and in
key personal. Due to the lack of continuity of data from
these laboratories, only the rate of positivity was investi-
gated in trends analysis. It is also acknowledged that the
removal of site/gender mismatch may have excluded valid
results from some transgender individuals. It is anticipated
that future analyses of ACCESS Laboratory Network data
will overcome this issue through the development of
processes to identify and include individuals that identify
as transgender.
Laboratories have only limited data on the patients
that they are testing. In particular, data on whether pa-
tients belong to certain priority populations – Aboriginal
and Torres Strait Islanders, sex workers, MSM (apart
from the surrogate measure of rectal swabs on men) –
are not available. That is why the ACCESS project com-
plements these laboratory data with data from clinical
networks. Further, all of these specimens are derived
from patients who sought health care, either because of
symptoms or perceived risk, so the data should be inter-
preted accordingly.
Despite these limitations, data presented here demon-
strates the ACCESS Laboratory Network can provide
unique and invaluable data. The GRHANITE system was
implemented successfully in each of these laboratories and
collated data that were meaningful and of high quality and
large volume. The ACCESS Laboratory Network data set
represents the most complete and extensive data set
on chlamydia testing among the general population in
Australia and will be an important resource for under-
standing chlamydia epidemiology into the future.
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Conclusion
The ACCESS Laboratory Network data are unique in both
number and scope and are representative of chlamydia
testing in both general practice and high-risk clinics. The
use of GRHANITE allowed the extraction of testing and
demographic data. Analysis of these data highlight much
lower levels of testing in young people aged 20 years or
less; in particular female patients aged less than 16 years,
despite being the group with the highest positivity rate.
Strategies are needed to increase the uptake of testing in
this high-risk group.
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